Imaging markers for Alzheimer disease: which vs how.

@article{Frisoni2013ImagingMF,
  title={Imaging markers for Alzheimer disease: which vs how.},
  author={Giovanni B. Frisoni and Martina Bocchetta and Gael Ch{\'e}telat and Gil D. Rabinovici and Mony J. de Leon and Jeffrey Kaye and Eric M. Reiman and Philip Scheltens and Frederik Barkhof and Sandra E. Black and David J. Brooks and Maria Chrisina Carrillo and Nick C. Fox and Karl Herholz and A. Nordberg and Clifford R. Jack and William J. Jagust and Keith A. Johnson and Christopher C. Rowe and Reisa A. Sperling and William Thies and Lars-Olof Wahlund and Michael W Weiner and Patrizio Pasqualetti and Charles DeCarli},
  journal={Neurology},
  year={2013},
  volume={81 5},
  pages={487-500}
}
Revised diagnostic criteria for Alzheimer disease (AD) acknowledge a key role of imaging biomarkers for early diagnosis. Diagnostic accuracy depends on which marker (i.e., amyloid imaging, ¹⁸F-fluorodeoxyglucose [FDG]-PET, SPECT, MRI) as well as how it is measured ("metric": visual, manual, semiautomated, or automated segmentation/computation). We evaluated diagnostic accuracy of marker vs metric in separating AD from healthy and prognostic accuracy to predict progression in mild cognitive… CONTINUE READING